Modulation of the Itaconate Pathway Attenuates Murine Lupus.

ABSTRACT:

Objective

Itaconic acid, a Krebs cycle-derived immunometabolite, is synthesized by myeloid cells in response to danger signals to control inflammasome activation, type I interferon (IFN) responses, and oxidative stress. As these pathways are dysregulated in systemic lupus erythematosus (SLE), we investigated the role of an itaconic acid derivative in the treatment of established murine lupus.

Methods

Female (NZW × NZB)F₁ lupus-prone mice were administered 4-octyl itaconate (4-OI) or vehicle starting after clinical onset of disease (30 weeks of age) for 4 weeks (n = 10 mice /group). At 34 weeks of age (peak disease activity), animals were euthanized, organs and serum were collected, and clinical, metabolic, and immunologic parameters were evaluated.

Results

SUBMITTER: Blanco LP 

PROVIDER: S-EPMC11337117 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature